CareDx divests Lab Products for $171.2M, refocusing U.S. precision medicine strategy
Jun 30, 2026, 4:09 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
A $171.2M cash infusion strengthens balance sheet, reduces non-core exposure, and could unlock higher-margin US-focused growth; pro forma details will clarify earnings impact, though the divestiture removes non-U.S. Lab Products revenue and may compress near-term top-line. Historically, exits of non-core assets via cash deals have supported multiple expansion if the core growth story remains solid.
AI summary
What happened, with direct paths to the underlying reporting
CareDx closed the Lab Products divestiture to Eurobio Scientific for $171.2 million, subject to post-closing adjustments, effective June 30, 2026. The sale narrows the company's portfolio to U.S. precision medicine testing services and digital solutions, aligning with a plan to invest in higher-growth areas such as specialty oncology. Pro forma impacts will be disclosed on the Q2 2026 earnings call.
CareDx completes Lab Products sale to Eurobio Scientific; closing June 30, 2026.
Cash consideration at closing: $171.2 million, subject to post-closing adjustments.
Sale includes IVD PCR kits and NGS-based assays outside North America.
Focus shifts to U.S. Precision Medicine Testing Services and Patient/Digital Solutions; pro forma details on Q2 call.
CEO: transaction sharpens focus and capital allocation toward high-growth areas like specialty oncology.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
CareDx has finalized the sale of its Lab Products division to focus on core Testing Services, which saw robust year-over-year growth. This transaction, which brings $170 million i…
- CDNA reported revenue of $72.05 million, down 6.7% over the same period last year. - EPS came in at -$0.03, compared to -$0.11 in the year-ago quarter. - Revenue from patient an…
- Expected quarterly loss of $0.19 per share, 72.7% decline from last year. - Revenue forecast of $63.63 million, down 17.7% year over year. - Consensus EPS estimate unchanged in…
